Novartis Pharmaceuticals
LOU064 (blinded)
Chronic Spontaneous Urticaria
Countdown
122days
Phase 3 readout · Nov 6, 2026
What's at stake
Phase 3 trial results for LOU064 (blinded) in Chronic Spontaneous Urticaria are due Nov 6, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05677451: Phase 3 trial, sponsor Novartis Pharmaceuticals, drug LOU064 (blinded). Primary completion date 2026-11-06 (estimated).”